FHA
ARIA

First Horizon Advisors’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

First Horizon Advisors’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2
Closed – – 1550
2013
Q4 		$0 Buy
+2
New +$11 ﹤0.01% 1458

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

First Horizon Advisors's ARIA Position: Q1 2014 in Review

First Horizon Advisors sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2014, closing a stake of 2 shares.

First Horizon Advisors first reported a position in ARIA in Q4 2013 and held it in 1 quarter. The position peaked at $0 in Q4 2013. 171 funds tracked by Wall St. Rank hold ARIA as of Q1 2014.

  • First Horizon Advisors reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2014 after selling out during the quarter.
  • First Horizon Advisors sold 2 Ariad Pharmaceuticals Inc shares in Q1 2014.
  • First Horizon Advisors first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 1 quarter.
  • First Horizon Advisors's Ariad Pharmaceuticals Inc position peaked at $0 in Q4 2013.
  • 171 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2014.

Based on First Horizon Advisors's 13F filing for Q1 2014, filed 2 May 2014.